Clinical Trials
4
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Zai Lab (Hong Kong), Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06462326
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: ZL-1102 3% w/w gel BID for 16 weeksDrug: ZL-1102 3% w/w gel QD for 16 weeksDrug: Placebo ZL-1102 0% w/w gel BID for 16 weeksDrug: Placebo ZL-1102 0% w/w gel QD for 16 weeksDrug: ZL-1102 1% w/w gel BID for 16 weeks
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Zai Lab (Hong Kong), Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT06380907
- Locations
- 🇦🇺
Zai Lab Site 5013, Phillip, Australian Capital Territory, Australia
🇦🇺Zai Lab Site 5021, Kogarah, New South Wales, Australia
🇦🇺Zai Lab Site 5016, Kotara, New South Wales, Australia
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
- Conditions
- Community-acquired Bacterial Pneumonia
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Zai Lab (Hong Kong), Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06162286
- Locations
- 🇨🇳
Beijing Tsinghua Chang Gung Hospital/Infectious Diseases Department, Beijing, China
🇨🇳Peking University Shougang Hospital/Respiratory and Critical Care Medicine Department, Beijing, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College/Intensive care unit, Bengbu, China
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Zai Lab (Hong Kong), Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05859464
- Locations
- 🇺🇸
Zai Lab Site 2005, Irvine, California, United States
🇺🇸Zai Lab Site 2007, Detroit, Michigan, United States
🇺🇸Zai Lab Site 2001, Hackensack, New Jersey, United States